CA2441755A1 - Proteines secretees humaines - Google Patents
Proteines secretees humaines Download PDFInfo
- Publication number
- CA2441755A1 CA2441755A1 CA002441755A CA2441755A CA2441755A1 CA 2441755 A1 CA2441755 A1 CA 2441755A1 CA 002441755 A CA002441755 A CA 002441755A CA 2441755 A CA2441755 A CA 2441755A CA 2441755 A1 CA2441755 A1 CA 2441755A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- polypeptide
- referenced
- fragment
- cdna clone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne des polypeptides sécrétés humains et des molécules d'acides nucléiques codant pour ces polypeptides, lesquels sont utiles pour diagnostiquer et traiter des maladies hématopoïétiques et hématologiques ainsi que des troubles et/ou des états pathologiques associés. La présente invention concerne également des anticorps se liant à ces polypeptides. Elle concerne en outre des vecteurs, des cellules hôtes ainsi que des méthodes de recombinaison et des méthodes synthétiques destinées à produire ces polynucléotides, ces polypeptides et/ou ces anticorps. Par ailleurs, l'invention porte sur des méthodes de criblage destinées à identifier des agonistes et des antagonistes des polynucléotides et des polypeptides susmentionnés. Elle se rapporte enfin à des méthodes et à des compositions destinées à inhiber ou accroître la production et la fonction de ces polypeptides.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27734001P | 2001-03-21 | 2001-03-21 | |
US60/277,340 | 2001-03-21 | ||
US30617101P | 2001-07-19 | 2001-07-19 | |
US60/306,171 | 2001-07-19 | ||
US33128701P | 2001-11-13 | 2001-11-13 | |
US60/331,287 | 2001-11-13 | ||
PCT/US2002/008277 WO2003038063A2 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2441755A1 true CA2441755A1 (fr) | 2003-05-08 |
Family
ID=27402891
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002441840A Abandoned CA2441840A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
CA002441832A Abandoned CA2441832A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
CA002441397A Abandoned CA2441397A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines humaines secretees |
CA002441755A Abandoned CA2441755A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
CA002441702A Abandoned CA2441702A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees par l'homme |
CA002441416A Abandoned CA2441416A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines humaines secretees |
CA002441417A Abandoned CA2441417A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees par les humains |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002441840A Abandoned CA2441840A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
CA002441832A Abandoned CA2441832A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
CA002441397A Abandoned CA2441397A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines humaines secretees |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002441702A Abandoned CA2441702A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees par l'homme |
CA002441416A Abandoned CA2441416A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines humaines secretees |
CA002441417A Abandoned CA2441417A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees par les humains |
Country Status (4)
Country | Link |
---|---|
EP (7) | EP1379132A4 (fr) |
AU (6) | AU2002320013A1 (fr) |
CA (7) | CA2441840A1 (fr) |
WO (7) | WO2003004622A2 (fr) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7196164B2 (en) | 1997-07-08 | 2007-03-27 | Human Genome Sciences, Inc. | Secreted protein HHTLF25 |
JP2002513295A (ja) | 1997-07-08 | 2002-05-08 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 123種類のヒト分泌タンパク質 |
US20060052321A1 (en) | 2002-04-05 | 2006-03-09 | Raitano Arthur B | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
US20040141975A1 (en) | 1998-06-01 | 2004-07-22 | Raitano Arthur B. | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
PT1086223E (pt) | 1998-06-01 | 2009-11-03 | Agensys Inc | Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações |
US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
WO2000042073A1 (fr) | 1999-01-15 | 2000-07-20 | Biogen, Inc. | Antagonistes de la proteine tweak et du recepteur de tweak, et leur utilisation pour traiter des affections immunitaires |
EP1666490A3 (fr) * | 2000-07-25 | 2006-11-02 | Genentech, Inc. | Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci |
US7291719B2 (en) | 2000-07-25 | 2007-11-06 | Genentech, Inc. | PRO4332 antibodies |
EP1364021A2 (fr) | 2000-10-31 | 2003-11-26 | Diadexus, Inc. | Compositions et methodes associees a des genes et a des proteines specifiques du colon |
US20020111302A1 (en) * | 2000-11-30 | 2002-08-15 | Y. Tom Tang | Novel nucleic acids and polypeptides |
US7736654B2 (en) * | 2001-04-10 | 2010-06-15 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
US20030119112A1 (en) | 2001-06-20 | 2003-06-26 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
ES2532757T3 (es) | 2001-09-06 | 2015-03-31 | Agensys, Inc. | Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer |
WO2003033727A1 (fr) | 2001-10-12 | 2003-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Procede de criblage d'un inhibiteur de la mort cellulaire |
CA2887716C (fr) | 2002-04-09 | 2017-01-24 | Biogen Idec Ma Inc. | Procede pour traiter les etats lies a tweak |
AU2003900747A0 (en) * | 2003-02-18 | 2003-03-06 | Garvan Institute Of Medical Research | Diagnosis and treatment of pancreatic cancer |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
WO2005019258A2 (fr) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions et methodes de traitement de maladies relatives au systeme immunitaire |
EP1670947B1 (fr) | 2003-09-23 | 2015-04-01 | University Of North Carolina At Chapel Hill | Technique et composition de correlation de polymorphisme nucleotidique simple dans le gene vitamine k epoxyde reductase et le dosage de warfarine |
JP4777251B2 (ja) * | 2003-10-14 | 2011-09-21 | バクスター・インターナショナル・インコーポレイテッド | ビタミンkエポキシド還元酵素複合体サブユニット1vkorc1、クマリンおよびその誘導体の治療標的 |
EP1714154A2 (fr) * | 2004-02-03 | 2006-10-25 | Bayer HealthCare AG | Agents diagnostiques et therapeutiques pour des maladies associes a la glutamate carboxypeptidase (pgcp) plasmatique |
US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
AU2004319915B9 (en) | 2004-04-22 | 2011-12-22 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
NZ553581A (en) | 2004-09-01 | 2011-04-29 | Dynavax Tech Corp | Methods and compositions for inhibition of innate immune responses and autoimmunity using immunoregulatory polynucleotides with a TGC sequence |
WO2006026808A1 (fr) * | 2004-09-07 | 2006-03-16 | Telethon Institute For Child Health Research | Methode de diagnostic et/ou de prediction du developpement d'une affection allergique |
JP2008512099A (ja) * | 2004-09-07 | 2008-04-24 | テレソン インスティテュート フォー チャイルド ヘルス リサーチ | アレルギー性疾患の処置または予防のための物質 |
AU2006214179A1 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
CN101124320A (zh) | 2005-02-28 | 2008-02-13 | 巴克斯特国际公司 | 重组共表达维生素k环氧化物还原酶亚基1以提高依赖维生素k的蛋白质表达 |
EP1861499A4 (fr) | 2005-03-15 | 2008-09-03 | Univ North Carolina | Procédés et compositions pour la production de protéines actives dépendantes de la vitamine k |
EP1885388B1 (fr) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Traitement et evaluation des troubles inflammatoires |
WO2006138219A2 (fr) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Procedes d'evaluation de patients |
US20090054307A1 (en) * | 2005-09-01 | 2009-02-26 | Howard Florey Institute Of Experimental Physiology And Medicine | Prophylactic and therapeutic agents and uses therefor |
GB0521488D0 (en) * | 2005-10-21 | 2005-11-30 | Ares Trading Sa | Integral membrane protein |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
ES2636089T3 (es) | 2006-10-27 | 2017-10-05 | Genentech, Inc. | Anticuerpos e inmunoconjugados y usos para los mismos |
JP5588175B2 (ja) | 2006-11-07 | 2014-09-10 | メルク・シャープ・アンド・ドーム・コーポレーション | Pcsk9のアンタゴニスト |
US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
CA2680832A1 (fr) * | 2007-03-27 | 2008-10-02 | Merck & Co., Inc. | Procede de detection de pcsk9 secretee, autogeneree |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
JP5749492B2 (ja) | 2007-10-26 | 2015-07-15 | ダイナバックス テクノロジーズ コーポレイション | 免疫応答と自己免疫を阻害する方法及び組成物 |
CA2707182C (fr) * | 2007-11-30 | 2017-12-12 | Siemens Healthcare Diagnostics Inc. | Fragments de recepteur de l'adiponectine et leurs procedes d'utilisation |
AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
WO2010068526A1 (fr) | 2008-12-12 | 2010-06-17 | Merck Sharp & Dohme Corp. | Immunodosage de pcsk9 |
AU2010313381A1 (en) | 2009-10-30 | 2012-04-12 | Merck Sharp & Dohme Corp. | AX1 and AX189 PCSK9 antagonists and variants |
CN102639150A (zh) | 2009-10-30 | 2012-08-15 | 默沙东公司 | Ax213和ax132 pcsk9拮抗剂和变体 |
BR112012032240A2 (pt) | 2010-06-16 | 2019-09-24 | Dynavax Technologies Corporation | método de tratamento utilizando inibidores tlr7 e/ou tlr9 |
CN105061534A (zh) | 2010-09-22 | 2015-11-18 | 艾丽奥斯生物制药有限公司 | 取代的核苷酸类似物 |
WO2012088222A2 (fr) | 2010-12-21 | 2012-06-28 | The University Of North Carolina At Chapel Hill | Procédés et compositions pour la production de protéines actives dépendantes de la vitamine k |
AU2012358804B2 (en) | 2011-12-22 | 2018-04-19 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9682218B2 (en) | 2013-12-23 | 2017-06-20 | Carefusion 2200, Inc. | Pleurodesis device and method |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
WO2018083248A1 (fr) | 2016-11-03 | 2018-05-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
AU2017382323B2 (en) | 2016-12-23 | 2024-06-13 | President And Fellows Of Harvard College | Gene editing of PCSK9 |
JP7247101B2 (ja) | 2017-04-03 | 2023-03-28 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Steap-1に結合する抗体 |
EP3642383B1 (fr) | 2017-06-22 | 2022-12-21 | The Procter & Gamble Company | Films comprenant une couche hydrosoluble et un revêtement inorganique déposé en phase vapeur |
EP3641951B1 (fr) | 2017-06-22 | 2023-09-20 | The Procter & Gamble Company | Films comprenant une couche hydrosoluble et un revêtement organique déposé en phase vapeur |
WO2021207711A2 (fr) | 2020-04-09 | 2021-10-14 | Verve Therapeutics, Inc. | Arn guides modifiés chimiquement pour l'édition du génome avec cas9 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100236393B1 (ko) * | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
WO2002026931A2 (fr) * | 2000-09-25 | 2002-04-04 | Human Genome Sciences, Inc. | 71 proteines humaines secretees |
US5858716A (en) * | 1997-05-30 | 1999-01-12 | Smithkline Beecham Corporation | H2CAA71 polynucleotides |
JP2002520050A (ja) * | 1998-07-15 | 2002-07-09 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 71個のヒト分泌タンパク質 |
-
2002
- 2002-03-19 EP EP02760994A patent/EP1379132A4/fr not_active Withdrawn
- 2002-03-19 WO PCT/US2002/008124 patent/WO2003004622A2/fr not_active Application Discontinuation
- 2002-03-19 WO PCT/US2002/009785 patent/WO2002095010A2/fr not_active Application Discontinuation
- 2002-03-19 CA CA002441840A patent/CA2441840A1/fr not_active Abandoned
- 2002-03-19 EP EP02759068A patent/EP1404702A4/fr not_active Withdrawn
- 2002-03-19 CA CA002441832A patent/CA2441832A1/fr not_active Abandoned
- 2002-03-19 EP EP02782476A patent/EP1414845A4/fr not_active Withdrawn
- 2002-03-19 AU AU2002320013A patent/AU2002320013A1/en not_active Abandoned
- 2002-03-19 CA CA002441397A patent/CA2441397A1/fr not_active Abandoned
- 2002-03-19 AU AU2002354719A patent/AU2002354719A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008276 patent/WO2002076488A1/fr not_active Application Discontinuation
- 2002-03-19 AU AU2002326293A patent/AU2002326293A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008279 patent/WO2002090526A2/fr not_active Application Discontinuation
- 2002-03-19 AU AU2002363296A patent/AU2002363296A1/en not_active Abandoned
- 2002-03-19 AU AU2002332391A patent/AU2002332391A1/en not_active Abandoned
- 2002-03-19 AU AU2002324424A patent/AU2002324424A1/en not_active Abandoned
- 2002-03-19 CA CA002441755A patent/CA2441755A1/fr not_active Abandoned
- 2002-03-19 CA CA002441702A patent/CA2441702A1/fr not_active Abandoned
- 2002-03-19 EP EP02749512A patent/EP1381622A2/fr not_active Withdrawn
- 2002-03-19 EP EP02799146A patent/EP1390390A4/fr not_active Withdrawn
- 2002-03-19 WO PCT/US2002/008123 patent/WO2002102993A2/fr not_active Application Discontinuation
- 2002-03-19 CA CA002441416A patent/CA2441416A1/fr not_active Abandoned
- 2002-03-19 EP EP02780789A patent/EP1423134A2/fr not_active Withdrawn
- 2002-03-19 CA CA002441417A patent/CA2441417A1/fr not_active Abandoned
- 2002-03-19 WO PCT/US2002/008277 patent/WO2003038063A2/fr not_active Application Discontinuation
- 2002-03-19 WO PCT/US2002/008278 patent/WO2002102994A2/fr not_active Application Discontinuation
- 2002-03-19 EP EP02723499A patent/EP1379264A4/fr not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2441755A1 (fr) | Proteines secretees humaines | |
CA2442777A1 (fr) | Proteines secretees par l'etre humain | |
CA2395885A1 (fr) | Acides nucleiques, proteines et anticorps | |
CA2393616A1 (fr) | Acides nucleiques, proteines et anticorps | |
JP2002518010A (ja) | 94個のヒト分泌タンパク質 | |
JP2002521055A (ja) | 98個のヒト分泌タンパク質 | |
JP2002533058A (ja) | 97個のヒト分泌タンパク質 | |
JP2002502600A (ja) | ヒトセリンプロテアーゼおよびセルピンポリペプチド | |
JP2001521383A (ja) | 20個のヒト分泌タンパク質 | |
JP2003528587A (ja) | 27個のヒト分泌タンパク質 | |
JP2002501738A (ja) | 67個のヒト分泌タンパク質 | |
JP2001514024A (ja) | 50個のヒト分泌タンパク質 | |
JP2003513662A (ja) | 15個のヒト分泌タンパク質 | |
EP1163334A1 (fr) | Polynucleotides et sequences d'acides amines derives de cellules de stroma | |
JP2003524366A (ja) | 64個のヒト分泌タンパク質 | |
JP2003521865A (ja) | 148個のヒト分泌タンパク質 | |
JP2003521215A (ja) | 83個のヒト分泌タンパク質 | |
JP2002532054A (ja) | 29個のヒト分泌タンパク質 | |
AU2002252266A1 (en) | Human serpin polypeptides | |
EP1572864A2 (fr) | Polypeptides du type serpine humaine | |
JP2001519156A (ja) | 101個のヒト分泌タンパク質 | |
US6184031B1 (en) | DNA sequences that encode a natural resistance to infection with intracellular parasites | |
JP4953487B1 (ja) | エラスターゼ阻害タンパク質およびその遺伝子 | |
JP2002500036A (ja) | ヒトfk506結合タンパク質 | |
EP1037984A1 (fr) | Polypeptiques de type cadherine, methodes et compositions connexes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |